# NATSAR PHARMACEUTICALS, INC.: Drug development of RK-33 for breast cancer treatment

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | NATSAR PHARMACEUTICALS, INC. |
| Location | ELLICOTT CITY, MD |
| Project | Drug development of RK-33 for breast cancer treatment |
| Project number | 5R44CA295155-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $615,189 |
| Awarded | 2026-09-17 |
| Project period | 2025-09-22 to 2027-08-31 |
| UEI | F2KMK7BBBMS3 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11419762). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.